AbbVie Patient Assistance Program Guide

——————————————————————————–

AbbVie manufactures some of the most widely prescribed and expensive medications in the United States, including Humira, Skyrizi, Rinvoq, and Venclexta. For patients without adequate insurance, these drugs can cost thousands of dollars a month at retail. The AbbVie Patient Assistance program — administered through the AbbVie Patient Assistance Foundation and known to patients as myAbbVie Assist — provides qualifying patients with certain AbbVie medications at no cost. This guide explains how the program generally works, who is eligible, and how to apply. Program terms, income limits, and covered drugs change over time, so treat the figures here as a starting point and verify current criteria with AbbVie before you rely on them.

Free Market Healthcare is an independent resource and is not affiliated with, endorsed by, or sponsored by AbbVie. We describe the program for educational purposes; the official source is AbbVie.

Overview of AbbVie Patient Assistance

myAbbVie Assist is AbbVie’s charitable initiative to help uninsured and underinsured patients access AbbVie medications. It is a patient assistance program (PAP), not insurance and not a copay coupon — approved patients receive their medication free of charge, typically shipped to their home or their prescriber’s office. The program covers a range of drugs used in immunology, oncology, and other therapeutic areas, and AbbVie reports having provided assistance to large numbers of patients over the years. Because it is administered as a foundation program, eligibility is based on residency, coverage status, and financial need rather than on being an AbbVie customer.

Medications Covered

The covered-product list spans much of AbbVie’s specialty portfolio and is updated periodically. Products that have been covered include:

• Humira (adalimumab) — for autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis (see the important 2026 change below)
• Skyrizi (risankizumab) — for plaque psoriasis, psoriatic arthritis, and certain inflammatory bowel conditions
• Rinvoq (upadacitinib) — for rheumatoid arthritis, atopic dermatitis, and ulcerative colitis, among others
• Venclexta (venetoclax) — for chronic lymphocytic leukemia and other blood cancers
• Imbruvica (ibrutinib) — for certain blood cancers
• Mavyret — for hepatitis C
• Others across neuroscience and additional areas (for example Vraylar, Ubrelvy, Qulipta, Linzess, and Creon have appeared on the list, and newer products are added over time)

Each medication may have slightly different eligibility criteria or application steps within the overarching myAbbVie Assist framework, and drugs can move on or off the list. Visit AbbVie.com or call 1-800-222-6885 to confirm that your specific medication is currently covered and to get the latest details.

Important 2026 Change for Humira

AbbVie has announced a significant change to Humira’s place in the program. Effective July 1, 2026, myAbbVie Assist will no longer accept new patients for Humira (adalimumab). Patients already enrolled are supported through the end of their current eligibility term, but when that term ends they will not be able to renew their Humira enrollment through the program. AbbVie says the change reflects the growing number of treatment options, including FDA-approved adalimumab biosimilars (such as Amjevita, Cyltezo, Hyrimoz, and Hadlima) that may be available through insurance or other support programs. If you take Humira, talk with your prescriber about whether a biosimilar is appropriate and what savings or assistance options apply to it, and confirm the current program terms directly with AbbVie.

Eligibility Requirements

To qualify for AbbVie Patient Assistance, you generally must meet these criteria: you are a U.S. resident; you have a valid prescription from a licensed U.S. healthcare provider treating you on an outpatient basis; and you have limited or no health insurance coverage for the AbbVie medication, along with demonstrated financial need. Patients with Medicaid coverage are generally not eligible. The exact rules can differ by product and change over time, so verify the current requirements before applying.

Income eligibility is based on household income and size. Rather than publishing a single poverty-level percentage, AbbVie typically lists dollar thresholds by household size, which work out to roughly 400% of the federal poverty level. For 2026, that is approximately $63,840 for one person and $132,000 for a family of four, with the threshold rising as household size grows. Some products may use different thresholds. Because these figures are updated and can vary by medication, verify the current income criteria for your specific drug with AbbVie; hardship exceptions may also be considered case by case.

Medicare Part D and the Extra Help Rule

Medicare interacts with the program in a specific way. myAbbVie Assist may be available to Medicare Part D beneficiaries who do not receive the Part D Low-Income Subsidy (Extra Help). Importantly, Part D patients with household income under 150% of the federal poverty level are generally required to apply for Extra Help first and be denied before they can qualify for the PAP. This is because Extra Help is meant to be the primary route to reduced Part D costs for low-income beneficiaries. If you have Medicare, ask AbbVie how the Extra Help requirement applies to your situation.

Separately, the 2026 Part D out-of-pocket cap of $2,100 limits total annual cost-sharing for covered Part D drugs, which can matter for beneficiaries who do not qualify for the PAP. The Medicare Prescription Payment Plan can also spread those out-of-pocket costs across the year.

How to Apply

The application usually begins with your healthcare provider. Your prescriber downloads the enrollment form from the AbbVie website or the specific drug’s patient support hub (such as Skyrizi Complete or Rinvoq Complete). The form requires the prescriber’s information, your diagnosis and prescribed medication, and your financial details.

You will typically need to submit proof of income — often your most recent federal tax return or recent pay stubs — along with a copy of a government-issued ID and a signed patient authorization. Your prescriber submits the completed package to myAbbVie Assist, and processing commonly takes a few weeks. Once approved, you receive medication on a schedule aligned with your dosing, often as a 90-day supply, and self-administered biologics ship in temperature-controlled packaging. Approval generally lasts up to about 12 months, after which you reapply with updated documentation.

AbbVie Copay Assistance for Insured Patients

If you have commercial insurance that covers an AbbVie medication but your copay is high, AbbVie offers separate copay assistance programs (distinct from the PAP). The Skyrizi Complete and Rinvoq Complete savings programs, for example, can reduce eligible commercially insured patients’ copays substantially. These copay cards cannot be used by patients with government insurance — Medicare, Medicaid, Tricare, or VA. For Medicare beneficiaries, Extra Help is the primary avenue for reducing Part D copays. Copay programs have annual benefit caps that vary by product, so review the terms for your specific medication.

Navigating the Humira Biosimilar Landscape

With adalimumab biosimilars such as Amjevita, Cyltezo, Hyrimoz, and Hadlima established in the U.S. market, patients who once depended on Humira now have more options. Biosimilars are often priced below the reference product, and — as noted above — AbbVie is directing new Humira patients toward these alternatives as it winds down Humira in the PAP. If you currently use Humira and a biosimilar could be a more affordable or accessible option through your insurance or a discount program, discuss the switch with your doctor. For broader comparisons of drug-savings options, visit our healthcare costs guide.

Alternative Savings Options

If you do not qualify for the AbbVie PAP, other resources may help. 340B pharmacies offer discounted pricing for patients at qualifying healthcare facilities. Prescription discount cards provide modest savings on some brand-name drugs, though discounts on specialty biologics are usually limited. State Pharmaceutical Assistance Programs may cover copays or provide supplemental drug coverage depending on your state.

Nonprofit organizations such as the Patient Access Network (PAN) Foundation, the HealthWell Foundation, and the Leukemia & Lymphoma Society also offer copay assistance for specific disease categories. Unlike manufacturer copay cards, these charitable programs are generally available to patients with insurance, including Medicare beneficiaries, when funding is open for the relevant fund.

Frequently Asked Questions

Can Medicare patients use AbbVie Patient Assistance?

Sometimes. Medicare Part D beneficiaries who receive Extra Help are generally not eligible for the PAP. Those without Extra Help may qualify, but patients under 150% of the poverty level are typically required to apply for Extra Help and be denied first. Call 1-800-222-6885 to discuss your specific coverage situation.

How long does it take to receive medication after approval?

After approval, the first shipment often arrives within a couple of weeks, and subsequent shipments follow your dosing schedule. For urgent situations, ask your prescriber or the patient support line whether a temporary bridge supply is available.

Does the program cover all AbbVie medications?

No. The AbbVie Patient Assistance program covers many, but not necessarily all, AbbVie products, and the list is updated periodically. Notably, Humira is closing to new PAP patients as of July 1, 2026. Call 1-800-222-6885 or visit AbbVie.com for the current list.

What happens if I gain insurance while enrolled?

If you obtain insurance that covers your AbbVie medication during your enrollment period, you must notify myAbbVie Assist. You will typically be transitioned off the PAP and may become eligible for copay assistance if your new coverage is commercial insurance. Continuing to use the PAP while insured violates program terms.

Is there a limit on how long I can use the program?

There is generally no lifetime limit. As long as you continue to meet eligibility requirements and reapply on schedule with updated documentation, you can receive covered medications through myAbbVie Assist — subject to product-specific changes like the Humira wind-down.

Access the Medications You Need

AbbVie’s specialty medications treat serious, chronic conditions that require consistent treatment, and myAbbVie Assist exists to keep cost from being a barrier for eligible patients. Talk to your healthcare provider about starting an application, or call 1-800-222-6885 for direct assistance — and always confirm the current eligibility rules and covered-drug list, since both change. For a fuller picture of prescription-savings options, explore our healthcare costs guide and related programs like the Rinvoq Patient Assistance Program.